Foghorn Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. filed this Current Report on Form 8-K on August 31, 2022. The filing reports a corporate governance change under Item 5.02 and identifies an accompanying press release as Exhibit 99.1.
Financial and Operating Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics. No financial statements are included.
Material Change Versus the Prior Comparable Period
- Cigall Kadoch, Ph.D., resigned from the Company’s Board of Directors effective immediately on August 31, 2022.
- The Company stated that Dr. Kadoch’s resignation did not involve any disagreement with the Company concerning its operations, policies, or practices.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide management guidance, business outlook, risk updates, contingencies, or unusual financial items. Exhibit 99.1 is identified as a press release issued August 31, 2022, but its contents are not included in the provided filing text.
Important Facts for Investors to Verify
- Confirm the effective date and circumstances of Dr. Kadoch’s board resignation.
- Review Exhibit 99.1 for any additional company commentary or disclosures.
- Check subsequent SEC filings for changes to board composition, committee assignments, or related governance matters.